Insights Into Breast Cancer 2022
Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease
Faculty Chair
William Gradishar, MD, FACP
Center for Women’s Cancer Care, Chicago, IL, USA
Faculty Chair
Mark Pegram, MD
Stanford Women’s Cancer Center, Palo Alto, CA, USA
Faculty Chair
Reshma Mahtani, DO
University of Miami Health System, Miami, FL, USA
Faculty Chair
Adam Brufsky, MD, PhD
UPMC Hillman Cancer Center, Pittsburgh, PA, USA
Faculty Chair
Jame Abraham, MD
Case Western Reserve University, Cleveland, OH, USA
Faculty Chair
William Gradishar, MD, FACP
Center for Women’s Cancer Care, Chicago, IL, USA
Faculty Chair
Melinda Telli, MD
Stanford University School of Medicine, Stanford, CA, USA
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual series
- National
More Information
- Philadelphia, PA
- Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of breast cancer
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
